Table 1.
Angiogenesis | Disease | Factor | Delivery Vector | Animal Model |
Injection | Result | Reference |
---|---|---|---|---|---|---|---|
Pro |
Ischemic Limb |
VEGF165 | Heparin-PEI | Mice | Intramuscular | Over 3-fold ↑ neovasulazation vs. PEI in ischemic limb |
[116] |
VEGF | PBAE | Mice | exwVoHUVEC transfection |
Limb salvage 50% compared to lipoplex (30%) and PEI (12.5%) |
[140] | ||
eNOS | Elastin-based polymer | Mice | Intramuscular | ~ 3-fold ↑ perfusion ratio and blood vessel density vs. control |
[120] | ||
Myocardial In fact |
Adreno- medulliln |
Dextran | Rats | ex vivo MSC transfection |
2.5-fold ↑ capillary density and 40% ↓ infarct size vs. control |
[131] | |
VEGF165 | Chitosan-g-PEI | Rats | Intramyocardial | 1.6-fold ↑ejection fraction and vessel density vs. PEI control |
[117] | ||
Hypoxia- inducible VEGF165 |
Cholesterol chloroformate-bPEI |
Rabbits | Intramyocardial | Myocardial infarct size (36% ↓) vs. vector alone without hypoxia- inducible VEGF165 |
[119] | ||
VEGF165 | PLGA | Rabbits | Intramyocardial | Capillary density (38% ↑) vs. plasmid only |
[124] | ||
Tissue Engineering |
SHh | PBAE | Mice | Transdermal | 15% ↑ wound closure than PBS | [150] | |
VEGF | PBAE | Mice | ex vivo ASC transfection |
20% ↑ wound closure than non- modified ASC |
[151] | ||
PDGF-B | PEI | Rats | collagen scaffold with PEI-pPDGF |
40% bone volume and 52-fold ↑ connective density vs. control |
[154] | ||
Anti | Cancer | sFlt-1 or siVEGFRI |
bPEI-g-PEG-cRGD | Mice | Intravenous | 3-fold / 42% ↓ colon carcinoma umor growth vs. PEI-g-PEG |
[214,216] |
NF-kB | Tween-SS-bPEI | Mice | Intravenous | Breast tumor volume 6% of saline | [218] | ||
Endostatin | PVP | Mice | Intramuscular | 60% ↓ metastatic brain tumor growth vs. control by MRI |
[220] | ||
shVEGF/ DOX | CPP-dendrimer PLL | Mice | Intravenous | VEGF mRNA (65% ↓) and median survival (2-fold ↑) vs. control in orthotopic glioma |
[224] | ||
siVEGF | guanidine-βCD-PEG- anisamide |
Mice | Intravenous | VEGF mRNA(3.5-fold ↓) / prostate tumor growth(3-fold ↓) vs. control |
[228] | ||
Age-related Macular Degenera tion |
Vasostatin | PVP | Rats | Intramuscular | 32.5% / 48% decrease in CNV incidence and area at day 42 |
[247] | |
shHIF-1α | PLGA | Rats | Intravitreal | Leakage (50%↓) / lesion thickness (40%↓) vs. control |
[248] | ||
Flt23k | RGD-PLGA | Monkey/ Mice |
Intravenous | CNV area 53% (monkey) and 43% (mice) ↓ vs. sham |
[252] |